FOLD
Price
$9.38
Change
-$0.03 (-0.32%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
2.91B
98 days until earnings call
Intraday BUY SELL Signals
RARE
Price
$32.92
Change
-$0.61 (-1.82%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
3.23B
91 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FOLD vs RARE

Header iconFOLD vs RARE Comparison
Open Charts FOLD vs RAREBanner chart's image
Amicus Therapeutics
Price$9.38
Change-$0.03 (-0.32%)
Volume$84.85K
Capitalization2.91B
Ultragenyx Pharmaceutical
Price$32.92
Change-$0.61 (-1.82%)
Volume$27.28K
Capitalization3.23B
FOLD vs RARE Comparison Chart in %
View a ticker or compare two or three
VS
FOLD vs. RARE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a StrongBuy and RARE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (FOLD: $9.42 vs. RARE: $33.53)
Brand notoriety: FOLD and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 92% vs. RARE: 70%
Market capitalization -- FOLD: $2.91B vs. RARE: $3.23B
FOLD [@Biotechnology] is valued at $2.91B. RARE’s [@Biotechnology] market capitalization is $3.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, FOLD is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • FOLD’s TA Score: 5 bullish, 4 bearish.
  • RARE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both FOLD and RARE are a good buy in the short-term.

Price Growth

FOLD (@Biotechnology) experienced а +2.50% price change this week, while RARE (@Biotechnology) price change was +5.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

FOLD is expected to report earnings on Feb 19, 2026.

RARE is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.23B) has a higher market cap than FOLD($2.91B). FOLD YTD gains are higher at: 0.000 vs. RARE (-20.300). FOLD has higher annual earnings (EBITDA): 33.1M vs. RARE (-435.33M). RARE has more cash in the bank: 477M vs. FOLD (231M). RARE has less debt than FOLD: RARE (36.3M) vs FOLD (443M). RARE has higher revenues than FOLD: RARE (610M) vs FOLD (571M).
FOLDRAREFOLD / RARE
Capitalization2.91B3.23B90%
EBITDA33.1M-435.33M-8%
Gain YTD0.000-20.300-
P/E RatioN/AN/A-
Revenue571M610M94%
Total Cash231M477M48%
Total Debt443M36.3M1,220%
FUNDAMENTALS RATINGS
FOLD vs RARE: Fundamental Ratings
FOLD
RARE
OUTLOOK RATING
1..100
2458
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
4156
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (55) in the Biotechnology industry is somewhat better than the same rating for RARE (97). This means that FOLD’s stock grew somewhat faster than RARE’s over the last 12 months.

FOLD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's SMR Rating (95) in the Biotechnology industry is in the same range as RARE (99). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's Price Growth Rating (41) in the Biotechnology industry is in the same range as RARE (56). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDRARE
RSI
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
75%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BCEGX21.340.13
+0.61%
Sterling Capital Equity Income C
TEWTX18.800.10
+0.53%
Templeton World C
RSINX16.840.05
+0.30%
Victory RS Investors A
FEGKX16.80N/A
N/A
Fidelity Equity Growth K6
JGACX33.98-0.07
-0.21%
JPMorgan Growth Advantage C

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with BMRN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+1.07%
BMRN - FOLD
46%
Loosely correlated
+0.71%
RARE - FOLD
45%
Loosely correlated
+0.84%
IMVT - FOLD
44%
Loosely correlated
+2.40%
CLDX - FOLD
44%
Loosely correlated
-0.49%
VCYT - FOLD
43%
Loosely correlated
-0.84%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+0.84%
MREO - RARE
70%
Closely correlated
-1.60%
NRIX - RARE
49%
Loosely correlated
-5.37%
TRDA - RARE
48%
Loosely correlated
+4.03%
IONS - RARE
48%
Loosely correlated
+0.30%
NUVL - RARE
48%
Loosely correlated
+0.91%
More